Get the Stockscreener App
10.05
2.05%
-0.21
Pre-market:
10.87
0.82
+8.16%
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Clinical Trials News Live Feed - StockTitan
Jennison Associates LLC Has $13.32 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat
Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial - MSN
Hypertension Drug Developer Mineralys Therapeutics Announces Critical Q4 Earnings Date - StockTitan
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025 - Marketscreener.com
Mineralys Therapeutics to Announce Fourth Quarter and Full - GlobeNewswire
Mineralys Completes Enrollment in Mid-Stage Hypertension Trial -February 04, 2025 at 11:43 am EST - Marketscreener.com
Mineralys Therapeutics Completes Enrollment in Explore-CKD - GlobeNewswire
Mineralys Therapeutics, Inc. Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3B CKD and Albuminuria - Marketscreener.com
Mineralys completes enrollment for hypertension drug trial - Investing.com India
Mineralys completes enrollment for hypertension drug trial By Investing.com - Investing.com South Africa
Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria - Marketscreener.com
Mineralys Therapeutics completes enrollment in Explore-CKD Phase 2 trial - TipRanks
Mineralys Therapeutics Completes Enrollment for Key Trial - TipRanks
Breakthrough CKD Trial Fully Enrolled: Mineralys Targets Silent Killer in Kidney Patients - StockTitan
Mineralys Therapeutics (NASDAQ:MLYS) Shares Up 5.1%What's Next? - MarketBeat
(MLYS) Technical Data - Stock Traders Daily
Mineralys Therapeutics Appoints Dr. Alexander Gold to Board Amid Hypertension Drug Development - MSN
Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension - Seeking Alpha
Barclays PLC Grows Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Holdings Boosted by Barclays PLC - Defense World
When (MLYS) Moves Investors should Listen - Stock Traders Daily
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy Sells 10,757 Shares - MarketBeat
Insider Sell: CEO Jon Congleton Sells Shares of Mineralys Therap - GuruFocus.com
Insider Sell: Adam Levy Sells Shares of Mineralys Therapeutics I - GuruFocus.com
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells $166,096.98 in Stock - MarketBeat
Mineralys Therapeutics CEO Jon Congleton sells $166,082 in stock By Investing.com - Investing.com Nigeria
Mineralys therapeutics CFO Adam Levy sells $97,863 in stock By Investing.com - Investing.com Australia
Mineralys Therapeutics CEO Jon Congleton sells $166,082 in stock - Investing.com India
Mineralys therapeutics CFO Adam Levy sells $97,863 in stock - Investing.com
Overcoming Barriers in Obesity and Hypertension Management: Practical Strategies for Physicians - Patient Care Online
Mineralys Therapeutics Receives FDA Clearance for Phase 2 Trial of Lorundrostat in Treating Sleep Apnea and Hypertension - MSN
Jane Street Group LLC Has $192,000 Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment - MyChesCo
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with HypertensionRADNOR, PA – January 8, 2025 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company f - Defense World
Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials - Yahoo Finance
Mineralys Therapeutics gets FDA nod for sleep apnea drug trial By Investing.com - Investing.com Nigeria
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat - Diagnostic and Interventional Cardiology
Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 9.6%Here's Why - MarketBeat
Mineralys Therapeutics : Corporate Overview January 2025 - Marketscreener.com
Mineralys Therapeutics Announces Phase 2 Clinical Trial of - GlobeNewswire
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension - Marketscreener.com
Mineralys Therapeutics gets FDA nod for sleep apnea drug trial - Investing.com
Mineralys Gets FDA Green Light for Sleep Apnea Drug Trial, Targets 54M Patient Market - StockTitan
Objective long/short (MLYS) Report - Stock Traders Daily
Neumora shares sink following Phase III flop in MDD - MSN
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Bought by Geode Capital Management LLC - Defense World
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):